BioXcel Therapeutics (BTAI) Tops Q4 EPS by 16c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q4 EPS of ($0.76), $0.16 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $376 thousand versus the consensus estimate of $742.86 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Global-e completes $350M acquisition of Passport logistics firm
• Biogen expects $164M R&D charge to hit Q2 2026 earnings